Effect of Highly Active Antiretroviral Therapy (HAART) and Hepatitis C Co-Infection on Hyperlipidemia in HIV-Infected Patients: A Retrospective Longitudinal Study

2002 ◽  
Vol 3 (6) ◽  
pp. 451-461 ◽  
Author(s):  
Patroni Andrea ◽  
Torti Carlo ◽  
Tomasoni Lina ◽  
Quiros Roldan Eugenia ◽  
Bertelli, Davide ◽  
...  
Keyword(s):  
Longitudinal Study ◽  
Hepatitis C ◽  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Highly Active

scholarly journals Patterns and Predictors of Changes in Adherence to Highly Active Antiretroviral Therapy: Longitudinal Study of Men and Women

2007 ◽  
Vol 45 (10) ◽  
pp. 1377-1385 ◽  
Author(s):  
M. Lazo ◽  
S. J. Gange ◽  
T. E. Wilson ◽  
K. Anastos ◽  
D. G. Ostrow ◽  
...  
Keyword(s):  
Longitudinal Study ◽  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Men And Women ◽  
Highly Active

scholarly journals Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag

2011 ◽  
Vol 1 (1) ◽  
pp. 5 ◽  
Author(s):  
Rajakrishnan Vijayakrishnan ◽  
Sourbha Dani ◽  
Aparna Ramasubramanian ◽  
Rekha Nair ◽  
Tony M. Samaha
Keyword(s):  
Hepatitis C ◽  
Antiretroviral Therapy ◽  
Treatment Response ◽  
Highly Active Antiretroviral Therapy ◽  
Standard Therapy ◽  
Receptor Agonist ◽  
Patient Treatment ◽  
Highly Active ◽  
Novel Agent ◽  
Haart Therapy

HIV-associated thrombocytopenia is a dis- ease which can be recurrent to standard therapy which includes highly active antiretroviral therapy (HAART) therapy, steroids and immunoglobulin. We report a patient with HIV and hepatitis C who presented with resistant thrombocytopenia. Treatment with Eltrombopag – a thrombopoeitin receptor agonist showed initial good response with recurrence of thrombocytopenia. This novel agent could be considered as a treatment option prior to splenectomy and may be useful as a tempo- rizing measure.

Sign in / Sign up

Export Citation Format

Share Document